Aurobindo Pharma Limited
Valuation (90/100) does the heavy lifting; financial trend (40/100) is the drag.
Buy zoneOur blended model reads Aurobindo Pharma Limited as a Buy at 67/100. On 25.4x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹1,620.5. Financial health scores 79/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,516.69 implies about 4% downside across 29 analysts. It clears 10 of 13 investability checks, with durability 53, valuation 80 and momentum 81 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹2,201.44.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-2.49% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy67Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 9.9%
- Pass: Low debt (D/E < 0.5): 0.21x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 6%
- Pass: Earnings growing: 2%
- Pass: Net margin ≥ 10%: 10.4%
- Pass: Current ratio > 1.5: 1.81
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.16
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter54.8%
- Institutions30.5%
- Public & other14.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Trading near its 52-week high.
- Financially solid — Altman Z 4.16.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~74% below our estimated fair value.
About Aurobindo Pharma Limited
Aurobindo Pharma develops and manufactures generic pharmaceuticals, active pharmaceutical ingredients, injectables, biosimilars, and peptides across multiple therapeutic areas including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, and anti-diabetics. The company offers formulations in oral solids, liquids, injectables, vaccines, and metered dose inhalers.
Aurobindo Pharma Limited — frequently asked questions
Is Aurobindo Pharma Limited a buy, hold or sell?
StocksWizard currently rates Aurobindo Pharma Limited (AUROPHARMA) a Buy, based on a blended score of 67/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Aurobindo Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Aurobindo Pharma Limited's fair value at about ₹2,751.8, versus a current price of ₹1,580.2 — roughly 74% upside. On that basis the stock looks undervalued by 74%.
Is Aurobindo Pharma Limited financially healthy?
Aurobindo Pharma Limited scores 79/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Aurobindo Pharma Limited's share price performed?
Aurobindo Pharma Limited is up 11% over three months, and last traded at ₹1,580.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.